Generics in Italy: Angelini's Positioning Play
Generics, whose only marketable differentiation is that they can sell for lower prices, had no place in this world. Nonetheless, Italy too has recognized the importance of cutting its drug budget and will likely encourage generic prescribing.
You may also be interested in...
Teva says it isn't worried about the more aggressive pricing strategies used by brand companies to blunt blockbuster generic launches. What if the world's largest generic company is wrong? Part II of this two-part series looks at the future of the generic drug industry.
Generic drug companies are riding high after the largest generic launch ever (Zocor) and arguably the cleverest (Plavix). But brand companies are fighting back, and they may succeed in taking away the biggest incentive fueling patent challenges.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.